Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,055 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Therapy 6 Weeks Clear all
Not listed Not applicable Interventional

Laser Therapy for Treating Hypertrophic Burn Scars in Children

NCT01653691
View directory record Official record
Conditions
Burn Scars
Interventions
Pulse-Dye Laser, Sham
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
9 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 13, 2026, 8:22 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

NCT06253520
View directory record Official record
Conditions
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 8:22 PM EDT
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 8:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Impact of Vaginal and IM Progestins on the Cervix

NCT01954095
View directory record Official record
Conditions
Preterm Birth, Short Cervical Length
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 1 Interventional

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Radiation Therapy, Tinostamustine
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 13, 2026, 8:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunological Responses of COVID-19 Vaccination

NCT05238467
View directory record Official record
Conditions
Cancer; Chemotherapy
Interventions
COVID antibody titers in the blood
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 13, 2026, 8:22 PM EDT
Active, not recruiting Not applicable Interventional Results available

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893
View directory record Official record
Conditions
Lymphocyte Depletion
Interventions
SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
Radiation · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

NCT00603798
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Not applicable Interventional

Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families

NCT00693563
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Scheduled Telephone Intervention
Behavioral
Lead sponsor
Jeanne Hoffman
Other
Eligibility
16 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bridge Reinvention

NCT03554733
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
ReInventing Yourself after SCI
Behavioral
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 13, 2026, 8:22 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Equitable Smoking Relapse Prevention

NCT05625685
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Dependence
Interventions
Quitbuddy, Control, SDoH Augmentation, SDoH Control
Other
Lead sponsor
Bryan W. Heckman
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 13, 2026, 8:22 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

NCT00939510
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, lenalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Robert Dreicer MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 4 Interventional Results available

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

NCT00177294
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 13, 2026, 8:22 PM EDT
Terminated Not applicable Interventional

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

NCT05526079
View directory record Official record
Conditions
Rectal Cancer
Interventions
Watchfuf waiting
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 8:22 PM EDT
Terminated Not applicable Interventional Results available

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

NCT00724061
View directory record Official record
Conditions
Lymphoma
Interventions
Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 13, 2026, 8:22 PM EDT
Not listed Not applicable Interventional

LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence

NCT06458660
View directory record Official record
Conditions
HIV/AIDS, Mental Health Issue
Interventions
LPP+: Mindfulness Meditation Delivered, LP
Behavioral
Lead sponsor
Guiding Right, Inc.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Not applicable Interventional

Effect of Osteopathic Manipulative Medicine on Parkinson Disease

NCT02107638
View directory record Official record
Conditions
Parkinson Disease
Interventions
OMM treatment arm, Counseling
Procedure · Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 13, 2026, 8:22 PM EDT
Terminated Phase 2 Interventional

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

NCT02047214
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TPI 287, Bevacizumab
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 13, 2026, 8:22 PM EDT
Recruiting Phase 2 Interventional

CMV CTLs in Neonates With CMV Infection

NCT05564598
View directory record Official record
Conditions
Congenital Cytomegaloviral (CMV) Disease
Interventions
CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy
Biological · Drug
Lead sponsor
New York Medical College
Other
Eligibility
0 Days to 21 Days
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 8:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

NCT04165330
View directory record Official record
Conditions
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
AL3818, Nivolumab Injection
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 13, 2026, 8:22 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Low Intensity Shockwave Therapy for Erectile Dysfunction

NCT04434352
View directory record Official record
Conditions
Erectile Dysfunction, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy, Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Due to Arterial Insufficiency
Interventions
Storz Duolith Low-Intensity Shockwave Therapy
Device
Lead sponsor
University of Virginia
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 13, 2026, 8:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 13, 2026, 8:22 PM EDT